A new graduate nurse preparing to administer medications knows that which of the following is required for a drug to move through the body?

Choice A reason: Metoprolol (beta-blocker) and furosemide (loop diuretic) are commonly used in heart failure. Furosemide may lower potassium, counteracting hyperkalemia (5.5 mEq/L), and metoprolol doesn’t significantly affect potassium. This combination poses less risk for hyperkalemia exacerbation, making it less concerning than potassium-sparing combinations.

Choice B reason: Furosemide promotes potassium excretion, potentially reducing hyperkalemia (5.5 mEq/L), while enalapril (ACE inhibitor) may increase potassium. However, furosemide’s effect often offsets enalapril’s, making this combination less likely to worsen hyperkalemia significantly compared to two potassium-sparing drugs, so this choice is less critical.

Choice C reason: Captopril (ACE inhibitor) and spironolactone (potassium-sparing diuretic) both increase potassium levels by reducing aldosterone activity, exacerbating hyperkalemia (5.5 mEq/L). In heart failure, this combination risks severe hyperkalemia, causing arrhythmias, making it the most concerning interaction requiring close monitoring or adjustment.

Choice D reason: Amlodipine (calcium channel blocker) and propranolol (beta-blocker) primarily affect blood pressure and heart rate, not potassium levels. Their interaction may cause bradycardia or hypotension but doesn’t worsen hyperkalemia (5.5 mEq/L), making this combination less concerning for the patient’s current electrolyte status.

Choice A reason: Drugs with a narrow therapeutic range, like digoxin, require plasma level monitoring to ensure concentrations remain within a safe and effective range. This prevents toxicity (e.g., arrhythmias) or subtherapeutic effects, as small dose changes can significantly alter blood levels, making monitoring critical for patient safety and efficacy.

Choice B reason: Intravenous administration does not inherently address the risks of a narrow therapeutic range. While it ensures rapid delivery, it increases toxicity risk due to immediate bioavailability. Monitoring plasma levels is more critical than the route to maintain safe and effective drug concentrations, making this choice less appropriate.

Choice C reason: Administering at intervals longer than the half-life may lead to subtherapeutic levels for drugs with a narrow therapeutic range, reducing efficacy. Consistent dosing and plasma level monitoring are needed to maintain steady-state concentrations within the therapeutic window, making this choice incorrect for managing such drugs.

Choice D reason: Teaching that maximum effects occur quickly is inaccurate for most narrow therapeutic range drugs, which often require steady-state concentrations over time. Without monitoring, toxicity or inefficacy risks increase. Patient education should focus on adherence and monitoring, not rapid effects, making this choice inappropriate.